ArticleInvestigative ophthalmology & visual science2026
Overexpression or Activation of Potassium Channel TASK-3 Protects Retinal Ganglion Cells and Restores Visual Function in Optic Nerve Crush.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study explored in a mouse model whether activation or upregulation of the two-pore domain potassium channel tandem pore domain acid-sensitive potassium channel 3 (TASK-3) in retinal ganglion cells (RGCs) could protect RGCs and reverse the vision loss arising through optic nerve injury. Methods: TASK-3 activity was assessed using patch-clamp electrophysiology. The optic nerve of each mouse was crushed, and the selective TASK-3 agonist CHET3 was applied to the surface of the eye once daily for 1 week or TASK-3 was overexpressed specifically in RGCs through infection with recombinant adeno-associated virus 1 week after optic nerve crushing. Numbers of RGCs and of intrinsic photosensitive RGCs were determined through fluorescence microscopy. Image-forming activity of RGCs in mice was assessed using flash visual evoked potentials, the visual cliff test, and the visual water maze task. The non-image-forming activity of intrinsic photosensitive RGCs was assessed using the pupillary light reflex test. Results: CHET3 treatment increased the number of RGCs surviving after optic nerve injury, and it improved their electrophysiological response, visual acuity, contrast sensitivity, and the sensitivity of pupillary light reflex. These effects were associated with decreased RGC excitability. TASK-3 overexpression in sparse RGCs surviving long-term optic nerve injury restored their image- and non-image-forming activities. Conclusions: These results suggest that pharmacological activation or upregulation of TASK-3 may be a promising therapeutic strategy to promote vision recovery after optic nerve injury or in eye disorders associated with RGC degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.